Possible fourth death tied to Tysabri

Share this article:
Biogen Idec has told the FDA a fourth patient may have contracted a potentially deadly brain disease after taking the company's multiple sclerosis (MS) drug Tysabri, a report in today's Boston Globe said.
The Globe obtained the report of the unconfirmed case under the Freedom of Information Act.
If the case is confirmed, it could make it more difficult to for Biogen Idec and Elan, co-marketers of the drug, to convince the FDA that Tysabri is safe. Because the disease, progressive multifocal lekoencephalopathy (PML), is so rare, each additional confirmed case magnifies the drug's potential risks.
The possible fourth PML patient is a 48-year-old woman who was taking Tysabri along with Avonex, another Biogen Idec MS drug. The possible new case is the third among MS patients who were taking both Tysabri and Avonex. Some doctors have speculated that the two drugs may together sufficiently weaken patients' immune systems to permit the PML infection.
An FDA spokeswoman said in the Globe report that the agency is "in communications" with Biogen Idec "on this case, as well as on the ongoing safety review."
A Biogen spokesman told the Globe, "We're in the middle of our ongoing safety evaluation of Tysabri. We hope to have our findings by the end of the summer. Beyond that we're not commenting on the particulars of our ongoing safety review." Biogen said it would discuss its findings with the FDA.
In February, Biogen Idec and Elan suspended sale of Tysabri and discontinued clinical trials after it was disclosed that one patient had died of PML and another was believed to have it. A third case of the disease was identified in March.
The FDA approved Tysabri in November after reviewing one year of data from planned two-year trials. It also shortened the approval process to six months from the date the companies submitted their application.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.